All Blogs

Oct 22, 2025

The pharmaceutical industry has always been a high-stakes arena, where years of research, billions of dollars, and countless clinical trials culminate in a single therapy reaching patients. Despite tremendous advancements, the traditional drug discovery process remains time-consuming, costly, and fraught with uncer...

Oct 24, 2025

The chronic pruritus drugs market is currently not highly competitive, with only a few chronic pruritus drugs approved for treatment, including KORSUVA/KAPRUVIA (Cara Therapeutics/CSL/ Vifor/Maruishi), LIVMARLI (Mirum Pharmaceuticals/Takeda), and BYLVAY/KAYFANDA (Mirum Pharmaceuticals/Takeda). However, the treatmen...

Oct 21, 2025

FDA Approves Genentech’s GAZYVA for Lupus Nephritis Genentech, a member of the Roche Group, announced that the FDA has approved GAZYVA (obinutuzumab) for the treatment of adult patients with active lupus nephritis (LN) receiving standard therapy. The approval is supported by data from the Phase II NOBILITY and P...

Oct 20, 2025

Peanut allergy is among the most common and serious types of food allergy, with prevalence increasing over the past few decades, particularly among younger populations. It usually first appears in childhood, with symptoms emerging as early as 4 months of age and most often within the first two years of life. Around...

Oct 17, 2025

Pfizer’s oncology pipeline has achieved a second positive phase III trial in HER2-positive breast cancer within roughly a year. This latest success involves TUKYSA, a HER2-targeted tyrosine kinase inhibitor that Pfizer acquired through its $43 billion purchase of Seagen. In patients with HER2-positive metastatic...

Oct 16, 2025

Scanogen Received FDA Breakthrough Device Designation for Rapid Bloodstream Infection Assay  On October 15, 2025, Scanogen Inc., a molecular diagnostics innovator developing next-generation infectious disease detection technologies, announced that the U.S. Food and Drug Administration (FDA) granted Breakthr...

Oct 15, 2025

The convergence of Artificial Intelligence (AI) and Remote Patient Monitoring (RPM) marks a pivotal shift toward predictive, continuous, and patient-centric healthcare. As chronic diseases rise globally, healthcare systems are under pressure to deliver timely, personalized interventions without overburdening hospit...

Oct 14, 2025

FDA Approves Boehringer’s JASCAYD as First New IPF Therapy in Over a Decade Boehringer Ingelheim’s JASCAYD (nerandomilast) has received FDA approval as an oral treatment for adults with idiopathic pulmonary fibrosis (IPF), marking the first new therapy for the condition in over a decade. JASCAYD is the first and...

Oct 13, 2025

Chronic pruritus, characterized by itching that persists for more than six weeks, is a multifaceted condition that may stem from dermatologic, systemic, neurologic, or psychogenic factors. It has a profound impact on patients’ quality of life and is increasingly recognized as a standalone clinical entity. DelveInsi...

Oct 10, 2025

Over a decade after launching one of the first treatments for idiopathic pulmonary fibrosis, Boehringer Ingelheim is rejuvenating its presence in the rare lung disease arena with a newly approved therapy. On October 7, the FDA approved JASCAYD, marking the first new IPF treatment in over ten years. The approval fol...